Profile data is unavailable for this security.
About the company
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
- Revenue in USD (TTM)9.41m
- Net income in USD-83.99m
- Incorporated2016
- Employees131.00
- LocationVBI Vaccines Inc160 Second Street, CambridgeCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 830-3031
- Fax+972 8948-0660
- Websitehttps://www.vbivaccines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goldenwell Biotech Inc | 1.08k | -114.27k | 19.80m | -- | -- | 368.37 | -- | 18,333.33 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Aprea Therapeutics Inc | 963.81k | -12.72m | 20.42m | 7.00 | -- | 0.7059 | -- | 21.18 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Apollomics Inc | 0.00 | -172.60m | 20.65m | 45.00 | -- | 0.4124 | -- | -- | -1.93 | -1.93 | 0.00 | 0.4607 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1016 | -- | -- | -- | 28.33 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 20.77m | 255.00 | -- | 0.1325 | -- | 8.34 | -39.39 | -39.39 | 1.02 | 63.47 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.51m | 20.79m | 7.00 | -- | 1.95 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 20.94m | 29.00 | -- | 2.42 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 21.13m | 27.00 | -- | 0.9219 | -- | 18.36 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 21.50m | 131.00 | -- | -- | -- | 2.28 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 21.66m | 19.00 | -- | 0.9027 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| AIM ImmunoTech Inc | 193.00k | -31.12m | 21.93m | 26.00 | -- | 4.66 | -- | 113.62 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 21.96m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 22.15m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Biora Therapeutics Inc | 544.00k | -111.08m | 22.50m | 58.00 | -- | -- | -- | 41.37 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Spruce Biosciences Inc | 10.13m | -46.75m | 23.25m | 22.00 | -- | 0.349 | -- | 2.30 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -16.75m | 23.40m | 12.00 | -- | 1.04 | -- | -- | -1.65 | -1.65 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -52.03 | -50.94 | -56.92 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 23.45m | 45.00 | -- | 2.68 | -- | 5.97 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to VBI Vaccines Inc's reporting currency: US Dollar USD
8.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 16 Apr 2024 | 1.26m | 4.40% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 626.44k | 2.18% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 184.44k | 0.64% |
| Geode Capital Management LLCas of 31 Mar 2024 | 143.62k | 0.50% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 108.44k | 0.38% |
| Cambridge Investment Research Advisors, Inc.as of 31 Mar 2024 | 84.08k | 0.29% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 57.34k | 0.20% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 32.99k | 0.12% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 31.81k | 0.11% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 31.19k | 0.11% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
